The awake prone position plays an important role in the treatment of hypoxemia and the improvement of respiratory distress symptoms in non-intubated patients. It is widely used in clinical practice because of its simple operation, safety, and economy. To enable clinical medical staff to scientifically and normatively implement prone position for awake patients without intubation, the committees of consensus formulation, guided by evidence-based methodology and Delphi method, conducted literature search, literature quality evaluation and evidence synthesis around seven topics, including indications and contraindications, evaluation, implementation, monitoring and safety management, termination time, complication prevention and health education of awake prone position. After two rounds of expert letter consultation, Expert consensus on implementation strategy of awake prone positioning for non-intubated patients in China (2023) was formulated, and provide guidance for clinical medical staff.
Dyspnea , Wakefulness , Humans , Consensus , Prone Position , China
BACKGROUND: Simiao pill module (SMM), a traditional Chinese medicine formula, has been widely used to treat gout and gouty arthritis. The goal of this study was to investigate the effects of SMM on epithelial-mesenchymal transition (EMT) and activation of NLR family pyrin domain containing 3 (NLRP3) inflammasome in a mouse model of potassium oxonate (PO)-induced chronic hyperuricemic nephropathy (HN). METHODS: Mice were randomly divided into the following four groups: control, HN model (PO), febuxostat (FEB)-treated (PO + FEB), and SMM-treated (PO + SMM) groups. Following 6 weeks of treatment, blood samples were collected and mice were sacrificed to collect kidney samples to study the biochemical parameters associated with renal function and histopathological changes associated with HN, respectively. The samples were analyzed for the expression of markers of EMT (collagen type 3, α-smooth muscle actin [α-SMA], fibronectin, vimentin and E-cadherin) and activation of NLRP3 inflammasome (NLRP3, apoptosis-associated speck-like protein [ASC], caspase-1, interleukin [IL]-1ß, and IL-18). RESULTS: Our results showed that hyperuricemia, impaired kidney function, and renal pathological characteristics induced by PO treatment were improved following treatment with SMM and FEB. Additionally, treatment with SMM and FEB decreased the expression of vimentin, collagen 3, fibronectin, and α-SMA, and increased the expression of E-cadherin. Moreover, NLRP3 inflammasome activation, as assessed by the increased expression of NLRP3, ASC, and caspase-1, and secretion of IL-1ß and IL-18, was inhibited by treatment with SMM and FEB. CONCLUSION: These results suggest that SMM inhibited EMT and NLRP3 inflammasome activation in chronic HN mice, and the beneficial effect of SMM was compared with a standard drug, FEB.
Hyperuricemia , Renal Insufficiency, Chronic , Animals , Mice , Actins , Cadherins/therapeutic use , Caspases , Disease Models, Animal , Epithelial-Mesenchymal Transition , Febuxostat , Fibronectins , Hyperuricemia/chemically induced , Hyperuricemia/drug therapy , Inflammasomes/metabolism , Interleukin-18 , NLR Family, Pyrin Domain-Containing 3 Protein/metabolism , Uric Acid , Vimentin
Tailor-made red thermally activated delayed fluorescence (TADF) molecules comprised of an electron-withdrawing pyrazino[2,3-f][1,10]phenanthroline-2,3-dicarbonitrile core and various electron-donating triarylamines are developed. They can form intramolecular hydrogen-bonding, which is conducive to improving emission efficiency and promoting horizontal orientation and show near infrared (NIR) emissions (692-710 nm) in neat films and red delayed fluorescence (606-630 nm) with high photoluminescence quantum yields (73-90%) in doped films. They prefer horizontal orientation with large horizontal dipole ratios in films, rendering high optical out-coupling factors (0.39-0.41). Their non-doped OLEDs exhibit NIR lights (716-748 nm) with maximum external quantum efficiencies (ηext,max ) of 1.0-1.9%. And their doped OLEDs radiate red lights (606-648 nm) and achieve record-beating ηext,max of up to 31.5%. These new red TADF materials should have great potentials in display and lighting devices.
Purely organic small molecules with thermally-activated delayed fluorescence have a high potential for application in organic light-emitting diodes (OLEDs), but overcoming severe efficiency roll-off at high voltages still remains challenging. In this work, we design and synthesize two new emitters consisting of electron-withdrawing benzoyl and electron-donating phenoxazine and 9,9-dihexylfluorene. Their electronic structures, thermal stability, electrochemical behaviors, photoluminescence property, and electroluminescence performance are thoroughly investigated. These new emitters show weak fluorescence in dilute solution, but they can emit strongly with prominent delayed fluorescence in the aggregated state, indicating the aggregation-induced delayed fluorescence (AIDF) character. The solution-processed OLEDs based on the two emitters show high external quantum efficiency of 14.69%, and the vacuum-deposited OLEDs can also provide comparable external quantum efficiency of 14.86%. Significantly, roll-offs of the external quantum efficiencies are very small (down to 0.2% at 1,000 cd m-2) for these devices, demonstrating the evidently advanced efficiency stability. These results prove that the purely organic emitters with AIDF properties can be promising to fabricate high-performance solution-processed OLEDs.
